Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Neoadjuvant FOLFIRINOX versus gemcitabine-chemoradiotherapie bij (borderline) resectabel pancreascarcinoom
nov 2025 | Chirurgie, Maag-darm-leveroncologie